A proof-of-concept study of sequential treatment with the HDAC inhibitor vorinostat following BRAF and MEK inhibitors in BRAFV600mutated melanoma.
Alaa EmbabySanne C F A HuijbertsLiqin WangRodrigo Leite de OliveiraHilde RosingBastiaan NuijenJoyce SandersIngrid HoflandCharlaine van SteenisRoelof J C KluinCor LieftinkChristopher G SmithChristian U BlankJohannes V van ThienenJohn B A G HaanenNeeltje SteeghsFrans L OpdamJos H BeijnenAlwin D R HuitemaRené BernardsJan H M SchellensSofie WilgenhofPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Intermittent treatment with vorinostat in patients with resistant BRAFV600mutated melanoma is well tolerated. Although the primary endpoint of this study was not met, durable anti-tumor responses were observed in a minority of patients (9%).